What question did this study set out to answer?

To compare the effectiveness of dapagliflozin and empagliflozin in reducing albuminuria and assessing eGFR decline in patients with diabetes and chronic kidney disease.

February 8, 2026Open Access

Comparison of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes and/or Chronic Kidney Disease: A Real-World Observational Study

View Full Paper

Ask AI

Bookmark

Authors

MYMehmet YilmazUniversity of Health Science EYEmre YaşarTurkish Armed Forces BABerrak Itir AyliHacettepe University

Discussion

Member takes

Implication

Retrospective observational study shows similar effectiveness in reducing albuminuria in diabetes and CKD populations, suggesting broad use of SGLT2 inhibitors.

Key Points

To compare the effectiveness of dapagliflozin and empagliflozin in reducing albuminuria and assessing eGFR decline in patients with diabetes and chronic kidney disease.
Retrospective observational study design
Evaluated 328 adults with diabetes and/or chronic kidney disease
Measured laboratory data over 12 months, including eGFR and albumin-to-creatinine ratio
Primary outcome focused on ≥50% reduction in albuminuria
61.4% of diabetic patients achieved ≥50% reduction in albuminuria after 12 months
High response rates noted across all patient subgroups, including those with isolated diabetes and diabetic kidney disease
Only one patient experienced a significant eGFR decline, with no notable differences between the two medications

Cite This Study

Yilmaz et al. (2025) studied this question.

synapsesocial.com/papers/698827c90fc35cd7a8846be3 https://doi.org/10.5281/zenodo.18442722

View Full Paper

Ask AI

Bookmark

Implication

Retrospective observational study shows similar effectiveness in reducing albuminuria in diabetes and CKD populations, suggesting broad use of SGLT2 inhibitors.

Comparison of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes and/or Chronic Kidney Disease: A Real-World Observational Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparison of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes and/or Chronic Kidney Disease: A Real-World Observational Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider